871022-62-7 Usage
Description
Tert-butyl (4-fluoropiperidin-4-yl)methylcarbamate is a chemical compound that serves as a reagent in the synthesis of cyanophenylglycine derivatives. These derivatives have the potential to act as reversible inhibitors of lysine demethylase 1, an enzyme that plays a crucial role in the differentiation of leukemia stem cells in acute myeloid leukemia (AML).
Uses
Used in Pharmaceutical Industry:
Tert-butyl (4-fluoropiperidin-4-yl)methylcarbamate is used as a reagent for the preparation of cyanophenylglycine derivatives, which are of interest in the development of treatments for acute myeloid leukemia (AML). The derivatives may function as reversible inhibitors of lysine demethylase 1, a key enzyme involved in the differentiation of leukemia stem cells, thus offering a potential therapeutic approach to combat AML.
Check Digit Verification of cas no
The CAS Registry Mumber 871022-62-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,1,0,2 and 2 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 871022-62:
(8*8)+(7*7)+(6*1)+(5*0)+(4*2)+(3*2)+(2*6)+(1*2)=147
147 % 10 = 7
So 871022-62-7 is a valid CAS Registry Number.
InChI:InChI=1/C11H21FN2O2/c1-10(2,3)16-9(15)14(4)11(12)5-7-13-8-6-11/h13H,5-8H2,1-4H3
871022-62-7Relevant articles and documents
HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2
-
Paragraph 0446-0448, (2020/02/16)
A compound of formula (I):wherein Ring A, Q, R1,R2, R3, R4, R5, R6, R7, R8, R9, R10, R11,X, a,b, c and d are as defined in the specification.
Benzimidazolone carboxylic acid derivatives
-
Page/Page column 38, (2008/06/13)
This invention relates to compounds of the formula (I): wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.